Caly für 0,49 und keiner kauft !

mit 0,29 völlig zufrieden Leute, glaube das es heute ein Rebound kommt, mindestens
15 % im Plus!!!!!!!




www.heinertreff.de  

nicht unbedingt 15%, aber rauf  

Kurs war doch after hours bereits wieder um 8,5% gestiegen auf 0,40 $. Klar geht's heute wieder rauf, darum ist der Kurs in F ja auch schon wieder bei 0,31/0,32.


Last Change (%) After Hours Chg (%)** Trade Time Bid Ask
0.40  0 (0.00)  0.0315 (8.55) 16:07 0 (0) 0 (0)

Die, die heute für unter 0,31 verkauft haben, sind's selbst schuld.


Grüße, ZN  

Es wird hier noch richtig abgehen und zwar nach oben da sind die 1,79 letzten Jahr ein Witz dagegen.
Caly testet den Urinschnelltest schon in Tailand laut Mitteilung von 23.März sollen darauf in den den nächsten 2-3- Wochen die Abschlußbesprechung erfolgen.
Caly baut ja laut letzten Bericht ( wenn ich das nicht falsch sehe), schon Produktionsstätten in China, Tailand , Russland
meint ihr die machen das ohne Produkt?
Marr steht dahinter mit all seinen Verbindungen in diesen Ländern.
Zusammengefasst:
Sobald der Verkauf von diesen Schnelltest beginnt in diesen Ländern, Freunde
gibt es viel viel viel Geld für Marr und für uns.
Amen.  

Hi, ich bin noch neu hier, ich bin Hollander, aber dieser hot stock will ich euch nicht enthalten. In Holland schonn riesen volumen, aber hier noch nicht......

http://www.quoteline.de/...sp?nws_id=1000300844&cmp_id=1000007816&l=D

Kuck es ihr nur mal objectiv an,.....

Gruss Heinz  

Habe mal 1000 Stück in mein Depot gestopft, vielleicht ist ja was dran ...wer weiss wusste schon damals das Microsoft mal so ein Monopol wird........;)

1000 langt ja um ein bisschen zu schnupern  

Recht hast du ja aber vergiss nicht das diese Länder auch finanzielle Propleme haben, sprich kein Geld für Kondome da werden die Leute wohl kaum Geld ausgeben für so einen Test das danach in die Mülltonne kommt!!!! Wir Europäer haben Angst um unser Leben weil wir viel zu verlieren haben, die Leute dort haben kaum was zu fressen, Aids ist dort nebensache.

Nur mal so zur INFO.....  

Da geb ich dir fast recht aber...
was nützt es einen Land wie China oder Russland wenn sie keine gesunden Bewohner mehr haben ?
also muß doch erst mal getestet werden wer hat HIV und wer nicht !
Das mit einen Produkt das schnell ist 99,97 % sicher ist und vorallem billig ist gegenüber den Speicheltest von Orasure!!.  

habe ja nicht gesagt das es schlecht ist nur gibts da halt diese kleinigkeiten die man nicht vergessen sollte !!!!

Egal hoffen wir heute erst mal auf ein guten Start !!!!!  

 

schlecht"?
Was treibst Du denn dort, wenn Du nicht hoffst,
dass Deine Akazien steigen?
Da kannst Du charten, planen, beobachten....was
immer Du willst, am Ende bleibt Dir nur die
Hoffnung.

Grüsse Pussy  

die fundamentals,oder die phantasie?=)

mfg kram  

also wenn ich keine hoffnung mehr hätte wären die zu 1 euro gekauften calys schon platt.statt dessen kaufe ich nach.bin also ein hoffnungsträger. löl
 

mir gehts bei caly auch nicht anders werde auch zu einem geeigneten zeitpunkt nachkaufen, der meines erachtens noch nicht da ist...

dafür schauts bei meinem softbank call supi aus... einmal top einmal flop das machts ja interessant ;o)

lg istvan4  

wo liegt denn deine kauforder?denke der tag wo wir im plus schließen ist heute.danach kurzfristig über 50 cent in usa, seitwärts bis zu neuen news und dann rauf, je nachdem obs ein vertrag gibt oder nicht.bin da allerdings guter dinge.gründe dafür wurden oft genug hier genannt. :O)
 

solange caly keinen boden gebildet hat bzw eine tendenz nach oben bildet ist ein weiterer einstieg für mich uninteressant - es kann zwar sein dass sie sich bald mit einem sprung richtung 0,50 USD bewegt (dann verpass ich was), allerdings sind die gefahren dass sie noch weiter richtung 0,25 USD marschiert deutlich höher!!! ich bleib noch zuseher - noch kauf ich nicht nach...

lg istvan4  

 

Calypte Launches International Manufacturing Initiative of its Rapid HIV Type 1 and HIV Type 2 Tests
Announces License and Supply Agreement with Adaltis, Inc. Memorandum of Understanding Signed for Initial Manufacturing of HIV-1/2 Rapid Tests in Thailand

THURSDAY , APRIL 01, 2004 09:17 AM

ALAMEDA, Calif., Apr 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT) a company engaged in developing rapid tests for HIV diagnosis and the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced that it has entered into an agreement with Adaltis, Inc. to license and supply certain peptides to Calypte that are owned by Adaltis for the use in the Company's immunodiagnostic assays. The first application for the peptides will be in the Company's HIV rapid diagnostic tests currently under development.

The agreement provides Calypte with the supply of key, patented HIV-Type 1 and HIV-Type 2 ("HIV-1/2") peptides by Adaltis. Calypte's non-exclusive license to Adaltis' peptide sequences provides the Company total freedom to operate throughout the world, with the exception of Canada, where Calypte would work with Adaltis in its home territory. Calypte is licensing the right to market and sell the peptides as part of the development of its rapid HIV diagnostic test products.

Dr. J. Richard George, President and CEO of Calypte stated, "We have used the Adaltis HIV-1/2 peptides in the field trials of our rapid tests in Thailand. Their consistency provides the foundation necessary to achieve the high levels of performance we require for both specificity (false negatives) and sensitivity (false positives). Our field trials have included our blood rapid HIV-1/2 test for which we filed an Investigational Device Exemption Application (IDE) in the US last November, as well as our urine rapid HIV-1/2 test. We have also tested the product in house with other fluids and are pleased with the initial results from both a specificity and sensitivity perspective and are planning to include this additional product in our upcoming field trials later this month."

Dr. George added, "In the community of like sciences, we were encouraged to see that OraSure received FDA approval for their laboratory based rapid oral fluid test for HIV-1. Once our non-laboratory based rapid tests are out of development and into production, we initially plan to distribute them outside the United States. We believe that Calypte's products will soon have world appeal, and after we have introduced our tests internationally, we expect to file for FDA approval for marketing in the US as well. However, our current focus is Sub-Saharan Africa and the "next wave" emerging HIV epidemic countries where the problem is more widespread -- including, China and Russia."

Tony Cataldo, Executive Chairman of Calypte stated, "As Calypte pursues the development of its rapid HIV-1/2 tests, we believe we are now far enough along in our development to begin finalizing the necessary agreements and to start transferring the technology to commercial scale manufacturing. The largest markets in the world are the emerging markets and we believe we are now well positioned to serve those markets. "

Calypte currently has a non-exclusive worldwide distribution agreement with Adaltis Inc. of Montreal, Canada for the distribution of Calypte's serum HIV-1 Western Blot test.

First International Manufacturing Initiative in Thailand

Calypte is preparing for its first foreign manufacturing technology transfer and today also announced that it has signed a Memorandum of Understanding with Thailand-based Pacific Biotech Co., Ltd. to act as Calypte's initial international manufacturer for both its urine and blood rapid tests. Manufacturing will be located at the Pacific Biotech facility in Phetchaboon, Thailand and a formal agreement is expected to be finalized around the middle of April.

Commenting on this arrangement, Dr. George stated, "I have been familiar with the capabilities of Pacific Biotech for several years, and have had past personal experience with them as an ISO 9001 certified contract manufacturer for rapid assays. Our recent audit of their facilities and quality systems tells me that they are an experienced and quality-minded organization that is eminently qualified to manage the manufacturing task ahead of them."

Ninlawan Pichayayothin, President of Pacific Biotech, stated, "The technologies and quality systems involved in this project are very familiar to us. We are confident that we can manufacture the Calypte tests at our facility in both the quality and quantity demanded."

Separately, Calypte confirmed that it continues its focus on China, which the Company believes will be its largest market. Beijing Calypte Biomedical Technology Ltd., the Company's joint venture with Marr Technologies Limited, Calypte's business partner and affiliate of Marr Technologies BV, which owns 28% of Calypte's common stock, has begun negotiations that are expected to lead to a manufacturing joint venture in China that will be controlled by Beijing Calypte. The Company is optimistic that this manufacturing relationship could facilitate a quick regulatory approval process in China.

 

kurzfassung für mi?
 

 

 

 

n/a    16:47:45    0.435    2'500  
n/a    16:47:45    0.436    2'500  
n/a    16:47:11    0.435    3'000  
n/a    16:47:11    0.436    3'000  
n/a    16:46:32    0.435    25'000  
n/a    16:45:49    0.436    4'000  
n/a    16:45:49    0.435    2'500  
n/a    16:45:42    0.435    25'000  
n/a    16:45:17    0.436    1'500  
n/a    16:44:49    0.429    15'000  
n/a    16:44:43    0.436    3'500  
n/a    16:44:28    0.435    2'500  
n/a    16:44:07    0.435    2'500  
n/a    16:44:04    0.44    800  
n/a    16:43:25    0.43    3'000  
n/a    16:43:18    0.44    10'000  
n/a    16:43:15    0.435    10'000  
n/a    16:43:05    0.375    15'000  
n/a    16:42:55    0.43    1'669  
n/a    16:42:53    0.375    1'435  
n/a    16:42:38    0.41    5'000  
n/a    16:42:19    0.432    2'500  
n/a    16:42:13    0.43    15'000  
n/a    16:41:53    0.432    20'000  
n/a    16:41:19    0.432    7'500  
n/a    16:41:17    0.432    8'000  
n/a    16:41:04    0.43    2'500  
n/a    16:41:03    0.43    10'000  
n/a    16:40:53    0.432    2'500  
n/a    16:40:39    0.43    15'000  
n/a    16:40:39    0.375    1'500  
n/a    16:40:39    0.375    1'000  
n/a    16:40:28    0.432    2'500  
n/a    16:40:28    0.432    400  
n/a    16:40:27    0.432    1'100  
n/a    16:40:27    0.43    3'000  
n/a    16:40:24    0.43    7'500  
n/a    16:40:21    0.375    3'000  
n/a    16:39:51    0.443    800  
n/a    16:39:50    0.443    10'000  
n/a    16:39:46    0.375    10'000  
n/a    16:39:28    0.375    28'000  
n/a    16:39:13    0.443    7'500  
n/a    16:39:11    0.443    15'000  
n/a    16:39:01    0.443    5'000  
n/a    16:38:56    0.43    10'000  
n/a    16:38:39    0.365    30'000  
n/a    16:38:20    0.43    7'500  
n/a    16:38:00    0.429    20'000  
n/a    16:37:58    0.42    1'000  
n/a    16:37:36    0.435    2'500  
n/a    16:37:36    0.435    2'500  
n/a    16:37:36    0.425    5'000  
n/a    16:37:34    0.435    20'000  
n/a    16:37:29    0.43    3'000  
n/a    16:37:26    0.425    1'000  
n/a    16:37:19    0.435    600  
n/a    16:37:19    0.435    3'000  
n/a    16:37:19    0.425    1'200  
n/a    16:37:19    0.435    2'000  
n/a    16:37:19    0.425    10'000  
n/a    16:37:19    0.425    2'000  
n/a    16:37:12    0.435    555  
n/a    16:37:07    0.42    3'000  
n/a    16:37:03    0.435    2'500  
n/a    16:36:47    0.435    2'475  
n/a    16:36:47    0.435    5'000  
n/a    16:36:47    0.42    5'000  
n/a    16:36:46    0.435    5'000  
n/a    16:36:43    0.419    6'000  
n/a    16:36:28    0.43    5'000  
n/a    16:36:17    0.42    10'000  
n/a    16:36:14    0.43    5'000  
n/a    16:36:07    0.42    2'500  
n/a    16:36:05    0.42    3'000  
n/a    16:36:05    0.42    2'500  
n/a    16:36:02    0.42    7'500  
n/a    16:36:01    0.415    7'500  
n/a    16:35:58    0.42    5'000  
n/a    16:35:57    0.39    6'000  
n/a    16:35:47    0.41    10'000  
n/a    16:35:33    0.42    5'000  
n/a    16:35:33    0.411    5'000  
n/a    16:35:16    0.375    5'000  
n/a    16:35:08    0.41    5'000  
n/a    16:34:58    0.41    5'000  
n/a    16:34:44    0.375    1'400  
n/a    16:34:37    0.375    5'000  
n/a    16:34:32    0.41    2'500  
n/a    16:34:26    0.41    5'000  
n/a    16:34:12    0.405    5'000  
n/a    16:34:08    0.4    7'500  
n/a    16:34:04    0.375    5'000  
n/a    16:34:02    0.405    4'000  
n/a    16:34:02    0.4    15'000  
n/a    16:33:57    0.405    5'000  
n/a    16:33:30    0.405    2'500  
n/a    16:33:28    0.405    2'500  
n/a    16:33:27    0.375    690  
n/a    16:33:21    0.405    2'500  
n/a    16:33:20    0.375    5'000  
n/a    16:33:14    0.4    1'000  
n/a    16:33:06    0.401    5'000  
n/a    16:33:03    0.405    2'000  
n/a    16:33:00    0.4    3'500  
n/a    16:33:00    0.4    1'800  
n/a    16:32:58    0.4    3'200  
n/a    16:32:58    0.4    875  
n/a    16:32:58    0.4    1'000  
n/a    16:32:46    0.4    25'000  
n/a    16:32:30    0.4    3'000  
n/a    16:32:29    0.4    2'500  
n/a    16:32:11    0.395    2'500  
n/a    16:32:00    0.395    3'000  
n/a    16:31:59    0.395    5'000  
n/a    16:31:58    0.39    5'000  
n/a    16:31:56    0.395    5'000  
n/a    16:31:55    0.39    5'000  
n/a    16:31:54    0.39    5'000  
n/a    16:31:53    0.395    2'500  
n/a    16:31:52    0.395    5'000  
n/a    16:31:51    0.39    5'000  
n/a    16:31:48    0.395    5'000  
n/a    16:31:44    0.395    10'000  
n/a    16:31:38    0.39    14'166  
n/a    16:31:35    0.395    5'000  
n/a    16:31:35    0.395    2'500  
n/a    16:31:35    0.395    2'500  
n/a    16:31:33    0.395    5'000  
n/a    16:31:32    0.395    5'000  
n/a    16:31:26    0.39    1'248  
n/a    16:31:12    0.395    2'500  
n/a    16:31:09    0.39    5'000  
n/a    16:31:08    0.395    5'000  
n/a    16:31:01    0.39    2'500  
n/a    16:30:55    0.39    1'000  
n/a    16:30:55    0.39    5'000  
n/a    16:30:55    0.39    1'000  
n/a    16:30:55    0.39    2'500  
n/a    16:30:55    0.39    5'000  
n/a    16:30:55    0.39    2'500  
n/a    16:30:55    0.39    2'500  
n/a    16:30:55    0.39    2'500  
n/a    16:30:55    0.39    2'500  
n/a    16:30:51    0.385    2'500  
n/a    16:30:51    0.39    2'500  
n/a    16:30:45    0.39    6'000  
n/a    16:30:45    0.385    6'000  
n/a    16:30:43    0.385    2'341  
n/a    16:30:41    0.385    2'500  
n/a    16:30:41    0.385    2'500  
n/a    16:30:40    0.39    5'000  
n/a    16:30:40    0.385    1'050  
n/a    16:30:40    0.385    4'000  
n/a    16:30:40    0.385    2'000  
n/a    16:30:40    0.39    4'000  
n/a    16:30:40    0.39    1'000  
n/a    16:30:40    0.39    2'000  
n/a    16:30:39    0.385    850  
n/a    16:30:39    0.39    850  
n/a    16:30:39    0.39    600  
n/a    16:30:39    0.385    600  
n/a    16:30:38    0.39    400  
n/a    16:30:38    0.39    4'000  
n/a    16:30:38    0.39    5'000  
n/a    16:30:38    0.39    3'950  
n/a    16:30:38    0.39    2'200  
n/a    16:30:38    0.385    5'000  
n/a    16:30:38    0.385    400  
n/a    16:30:38    0.385    4'000  
n/a    16:30:38    0.385    5'000  
n/a    16:30:38    0.385    2'200  
n/a    16:30:38    0.385    5'000  
n/a    16:30:38    0.39    5'000  
n/a    16:30:38    0.39    5'000